Goldberg Ellen 4

What Happened
Ellen Goldberg, a director of Castle Biosciences (CSTL), converted 13,667 restricted stock units (RSUs) into 13,667 shares on May 22, 2026. The Form 4 shows an acquisition of 13,667 shares through exercise/conversion of a derivative (code M) and a simultaneous disposition of the derivative instrument for $0.00 — indicating the RSUs settled into common stock with no cash paid or received.

Key Details

• Transaction date: 2026-05-22 (reported on Form 4 filed 2026-05-27).
• Transaction codes: M = exercise/conversion of derivative security; Acquired 13,667 shares (price N/A), Disposed 13,667 derivative units at $0.00.
• Shares owned after the transaction: Not specified in the provided filing.
• Footnotes: F1 — Each RSU converts to one share of common stock. F2 — These RSUs vest in full on the earlier of the one-year anniversary of May 22, 2026, or the day before the next annual meeting following the grant date.
• Timeliness: The Form 4 was filed five days after the transaction (filed 2026-05-27 for a 2026-05-22 transaction), which appears later than the typical Form 4 deadline (two business days) and may warrant a disclosure note.

Context
This was a non-cash settlement of RSUs (derivative conversion), not an open-market purchase or sale. The filing shows the derivative instrument was converted into shares rather than a cash exercise or immediate sale of the shares. Receipt/vesting of awards is common for directors and does not necessarily signal a buy/sell decision; it reflects compensation or previously granted awards being settled. The late filing is a reporting detail to note but does not change the economic effect of the transaction.